Filtrer vos résultats
- 3
- 3
- 3
- 3
- 3
- 3
- 3
- 3
- 3
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 3
- 3
- 3
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
triés par
|
|
PFOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases (RCSM): Final results of the FFCD 1102 phase II trialthe 42nd ESMO Congress (ESMO 2017), Sep 2017, Madrid, Spain. pp.505P, ⟨10.1093/annonc/mdx393.031⟩
Communication dans un congrès
hal-01632415v1
|
||
|
609TiPPRODIGE 50 - ASPIK French: French double blind randomised study of aspirin versus placebo in resected stage III or high risk stage II colon cancer with PIK3CA mutationthe 42nd ESMO Congress (ESMO 2017), Sep 2017, Madrid, Spain. ⟨10.1093/annonc/mdx393.134⟩
Communication dans un congrès
hal-01632463v1
|
||
|
Predictive factors for early progression during induction chemotherapy (IC) and chemotherapy-free interval (CFI): Analysis from PRODIGE 9 trialThe 42nd european society for medical oncology Congress, Sep 2017, Madrid, Spain. pp.557P, ⟨10.1093/annonc/mdx393.083⟩
Communication dans un congrès
hal-01626216v1
|